Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. (AMYLOCARTESIAN)
Primary Purpose
Heart Disease, Aging, Amyloidosis
Status
Active
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
a basal LV septum biopsy
Sponsored by
About this trial
This is an interventional screening trial for Heart Disease focused on measuring Amyloidosis, echocardiography, magnetic resonance imaging, radionuclide imaging
Eligibility Criteria
Inclusion Criteria:
- Significant aortic stenosis. The aortic stenosis severity (aortic area : <1cm² or <0.6cm²/m² measured by echocardiography
- Indication of surgical aortic valve replacement for AS: will be defined in each center in accordance with ESC guidelines.
- Patient ≥ 70 years old and NYHA class ≥2 and LVEF <60% or global LV strain more than "-17%".
- Written consent prior to surgery.
Exclusion Criteria:
- Other severe disease with a life prognosis below than 1 year.
- Already known other causes of amyloidosis than senile amyloidosis will be excluded.
- Patients unsuitable for AS surgery as defined by ESC guidelines 2012.
- Significant mitral valve disease needing a surgical treatment.
- Significant aortic regurgitation (class >III).
NB: Patients with pacemaker will be included but will not perform the cardiac MRI.
Sites / Locations
- Hôpital Henri Mondor
- CHU Limoges
- CHU LYON
- Chu Rennes
- Centre Cardiologique du Nord
- CHU de Toulouse
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
elderly patients with Aortic steNosis valvular replacement
Arm Description
Outcomes
Primary Outcome Measures
Clinical composite criterion: All causes of death and cardiovascular hospitalization at 1 year after surgery
All causes of death and cardiovascular hospitalization at 1 year after surgery
Secondary Outcome Measures
Full Information
NCT ID
NCT02260466
First Posted
October 6, 2014
Last Updated
September 30, 2022
Sponsor
French Cardiology Society
Collaborators
Pfizer, Henri Mondor University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02260466
Brief Title
Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.
Acronym
AMYLOCARTESIAN
Official Title
AMYLO-CARTESIAN Study :Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 2014 (undefined)
Primary Completion Date
July 31, 2023 (Anticipated)
Study Completion Date
July 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
French Cardiology Society
Collaborators
Pfizer, Henri Mondor University Hospital
4. Oversight
5. Study Description
Brief Summary
Background: The prevalence of both senile cardiac amyloidosis (CA) and aortic stenosis (AS) markedly increases with age. Aortic stenosis increases left ventricular pressure overload. Cardiac deposits have been observed in AS and the amount of these deposits has been correlated to post-surgical outcome. As they are strong echocardiographic and cardiac MRI imaging similarities between CA and AS, the investigators hypothesized that the deposit observed in AS is transthyretin amyloid deposit. The investigators objective is to demonstrate that amyloid deposit is associated with poor outcomes following aortic stenosis surgical valve replacement.
Materiel and methods: 180 patients with indication for surgical aortic valve replacement will be recruited prospectively and consecutively in 5 French centers. A replicative study will be performed in one Austrian center. Echocardiography, cardiac MRI and bone scintigraphy will be performed prior to surgery. During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion. Clinical outcomes will be recorded during the hospitalization period following the surgery and at 1 year. Alive and re-hospitalization status will be determined. Patients will be classified according to the presence or not of amyloid deposits.
Expected results and impact: This study will emphasize how pressure overload stress accelerates and magnifies amyloid deposition usually known to be related to cardiac aging process. It will develop reliable imaging tools and markers to detect cardiac amyloid deposition. Correlation between anatomopathologic analyses and the three different imaging technics will identify accurate imaging markers of CA. A risk stratification model based on amyloid deposits level for the clinical management of these patients will be created combining imaging and biological markers.
Detailed Description
Cardiovascular diseases remain the major cause of mortality and morbidity in industrialised countries. Their prevalence increases steeply as consequence of the aging of the population in these countries. Curiously, cardiovascular and neurodegenerative diseases share common aging pathological pathways involving abnormal accumulation of insoluble amyloid proteins in the extracellular matrix disrupting normal organ function. Whereas neurological amyloid diseases has been considerably investigated, little attention has been paid to the aggregation of amyloid proteins in cardiovascular diseases. Post-mortem studies have identified cardiac wild-type transthyretin amyloidosis deposition in 25% of individuals over the age of 80 years leading to the concept of "senile cardiac amyloidosis" (CA) (Cornwell, Am j Med 1984; Pitkanen, Am J Pathol 1984). The cause of this deposition is not yet known but might be related primarily to aging process and enhanced by cardiac mechanical stress (overload), hypoxia, oxidative stress and inflammation. Since patients with transthyretin CA develop severe heart failure with poor prognosis, it is crucial to identify them especially among population at risk such those with aortic stenosis (AS). Indeed this common valvular heart disease affects mainly senescent subjects and combines so the adverse effects on myocardial function of both pressure overload and myocardial aging.
Interestingly, some elderly patients with severe AS exhibit similar echocardiographic and cardiac MRI patterns as those reported in CA including increased cardiac wall thickness and progressive left ventricular dysfunction starting with alteration of basal LV-2D strain. They also exhibit increased late gadolinium enhancement (LGE) at cardiac MRI. This has been interpreted as related to interstitial myocardial "fibrosis" and has been correlated with poor prognosis after aortic valve replacement i.e.; high mortality, persistence of heart failure symptoms and LV dysfunction (Weidemann Circ 2009; Dweck, JACC 2011; Hermann JACC 2011). However none of these patients have benefited from a detailed histology analysis with aiming at identifying amyloid deposits. The investigators have recently found similar clinical observations in the investigators AS cohort. Using specific staining, the investigators were able to unmask the association of severe AS and CA in these patients. These preliminary findings raise the question of a potential pathophysiological link between CA and AS and might explain why some patients with AS may not benefit from cardiac surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Disease, Aging, Amyloidosis, Aortic Valve Stenosis
Keywords
Amyloidosis, echocardiography, magnetic resonance imaging, radionuclide imaging
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
186 (Actual)
8. Arms, Groups, and Interventions
Arm Title
elderly patients with Aortic steNosis valvular replacement
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
a basal LV septum biopsy
Intervention Description
During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
Primary Outcome Measure Information:
Title
Clinical composite criterion: All causes of death and cardiovascular hospitalization at 1 year after surgery
Description
All causes of death and cardiovascular hospitalization at 1 year after surgery
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Significant aortic stenosis. The aortic stenosis severity (aortic area : <1cm² or <0.6cm²/m² measured by echocardiography
Indication of surgical aortic valve replacement for AS: will be defined in each center in accordance with ESC guidelines.
Patient ≥ 70 years old and NYHA class ≥2 and LVEF <60% or global LV strain more than "-17%".
Written consent prior to surgery.
Exclusion Criteria:
Other severe disease with a life prognosis below than 1 year.
Already known other causes of amyloidosis than senile amyloidosis will be excluded.
Patients unsuitable for AS surgery as defined by ESC guidelines 2012.
Significant mitral valve disease needing a surgical treatment.
Significant aortic regurgitation (class >III).
NB: Patients with pacemaker will be included but will not perform the cardiac MRI.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thibaud DAMY, MD PhD
Organizational Affiliation
CHU Henri Mondor, Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Henri Mondor
City
Creteil
ZIP/Postal Code
94010
Country
France
Facility Name
CHU Limoges
City
Limoges
ZIP/Postal Code
87000
Country
France
Facility Name
CHU LYON
City
Lyon
ZIP/Postal Code
69000
Country
France
Facility Name
Chu Rennes
City
Rennes
ZIP/Postal Code
35000
Country
France
Facility Name
Centre Cardiologique du Nord
City
Saint-Denis
ZIP/Postal Code
93200
Country
France
Facility Name
CHU de Toulouse
City
Toulouse
ZIP/Postal Code
31059
Country
France
12. IPD Sharing Statement
Learn more about this trial
Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.
We'll reach out to this number within 24 hrs